期刊文献+

Septin2在霍奇金淋巴瘤细胞株L428细胞中的表达及其在促进细胞再分化中的作用 被引量:1

Expression of Septin2 in Hodgkin lymphoma cell line L428 and its role in promoting H/RS cells'redifferentiation to B lymphocytes
原文传递
导出
摘要 目的探索GTP结合蛋白氯苄乙胺2(Septin2)在霍奇金淋巴瘤细胞株L428细胞中的表达及其在H/RS(Hodgkin/Reed—Sternberg)细胞向B细胞再分化中的作用。方法采用实时荧光定量PCR(RT-qPCR)、Westernblot、激光共聚焦显微镜、免疫细胞化学法检测霍奇金淋巴瘤细胞株L428细胞过表达CD99前后Septin2在mRNA和蛋白水平的表达;采用RT-qPCR和Westernblot检测L428细胞转染Septin2干扰片段(Septin2-siRNA)后Septin2的表达;采用激光共聚焦显微镜、CCK8法和流式细胞术检测干扰Septin2基因对L428细胞骨架蛋白、细胞增殖活性和免疫表型的影响。结果与L428细胞空白对照组比较,L428细胞Septin2mRNA表达水平在CD99过表达后(O.329±0.019对1.000,P=0.001)和转染Septin2-0siRNA后(0.276±0.025对1.000,P=0.000)均下降,蛋白表达水平也下降。与转染空载体组比较,转染Septin2-siRNA后的L428细胞较前者胞体缩小,细胞增殖活性下降(F=204.927,P〈0.001),细胞中的微丝骨架发生了重建,CD30和CD15表达下降,CD19、CD10、CD38表达增高。结论Septin2在L428细胞中高表达,干扰Septin2可促进H/RS细胞向B细胞方向再分化。 Objective To explore the role of GTP binding protein 2 (Septin2) in the differentiation of Hodgkin' s Lymphoma H/RS cells (Hodgkin/Reed- Sternberg) to B lymphocytes. Methods The expressions of Septin2 mRNA and protein in Hodgkin' s Lymphoma cell line L428 which CD99 was overexpressed were detected by RT-qPCR and Western blot,confocal laser microscopy and immunocytochemistry (ICC). RT-qPCR and Western blot were used to assay the expression of Septin2 after Septin2-siRNA transfected into L428 cells, and confocal laser microscopy, CCK8 assay and flow cytometry were used to analyze the changes of F-actin cytoskeleton,cell proliferation ability and immunophenotype. Results The low expressions of Septin2 mRNA and protein were detected in L428 cell line after overexpresion of CD99 (0.329±0.019 vs 1.000, P=0.001) and Septin2 siRNA transfection (0.276± 0.025 vs 1.000, P=0.000) compared to controls. Compared to vector group, Septin2 siRNA transfection could lead to decrease of cell size, decline of proliferation activity (F=204.927, P〈0.001 ) and reconstruction of F-actin cytoskeleton, and the expression of specific antigen markers CD30 and CD15 of H/RS cell decreased, B cell antigen marker CD19 as well as germinal center marker CD10 and early plasma cell marker CD38 were up-regulated. Conclusion Septin2 interference promotes H/RS cells' redifferentiation to B lymphocytes
作者 孙清灿 钟琳 丘波 赵彤 周新华 Sun Qingcan Zhong Lin Qiu Bo Zhao Tong Zhou Xinhua(Department of Pathology, Southern Medical University, Guangdong Province Key Laboratory of Molecular Tumor Pathology, Guangzhou 510515, China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2017年第2期134-139,共6页 Chinese Journal of Hematology
基金 国家自然科学基金(81302051) 广东省自然科学基金(2014A030313284)
关键词 霍奇金病 氯苄乙胺 L428细胞 里德-斯特恩伯格细胞 细胞分化 Hodgkin disease Septins L428 cells Reed-Sternberg cells Cell differentiation
  • 相关文献

参考文献2

二级参考文献18

  • 1Siegel R, Ward E, Brawley O, et al. Cancer statistics,2011:the impact of eliminating c and racial disparities on premature cancer deaths[J].CA Cancer J Clin, 2011, 61 (4):212- 236.
  • 2董颖,陈赛娟.淋巴瘤的流行病学//沈志祥,朱雄增.恶性淋巴瘤[M].2版.北京:人民卫生出版社,2011:25-26.
  • 3Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy Hodgkin' s lymphoma: final results of the GHSG HD7 trial [J]. J Clin Oncol, 2007, 25 (23) :3495-3502.
  • 4Johnson PW, Radford JA, Culien MH, et al. Comparison of ABVD and alternation or hybrid multidrng regimens for the treatment of advanced Hodgkin' s lymphoma:results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519) [J]. J Clin Oncol, 2005, 23 (36):9208- 9218.
  • 5Federico M, Luminari S, Iannitto E, et al. ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin' s lymphoma:results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial [J]. J Clin Oncol, 2009, 27(5):805-811.
  • 6Jaffe ES. The 2008 WHO classification of lymphomas:implica- tiona for clinical practice and translational research [ J ]. Hematol- ogy Am Soc Hematol Educ Program, 2009, 1 ( 1 ) :523-531.
  • 7Punnett A, Tsang RW, Hodgson DC. Hodgkin lymphoma across the age spectrum: epidemiology, therapy, and late effects [J]. Semin Radiat Oncol, 2010, 20( 1 ):30-44.
  • 8Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early stage Hodgkin lymphoma [J]. N Engl J Med, 2010, 363 (7) : 640-652.
  • 9Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin' s disease [J]. N Engl J Med, 2007, 357(19) :1916-1927.
  • 10Thomas J, Ferme C, Noordijk E, et al. Results of the EORTC- GELA H9 randomized trials: the H9-F trial ( comparing 3 radia- tion dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin's lymphoma[J]. Haematologica, 2007, 92( 1 ):27-34.

共引文献8

同被引文献3

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部